Combination therapy for advanced rectal cancer with RAS mutation
Treatments studied
Part of Cancer clinical trials.
This trial is testing a combination of chemotherapy and targeted therapy with or without adding radiation and two immunotherapy drugs for advanced rectal cancer that has spread. It looks at whether adding radiation and immunotherapy can help control the cancer better for people with certain genetic types (RAS mutation and pMMR).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old
- Your rectal cancer must be stage IV with a KRAS or NRAS mutation and be 'pMMR' (mismatch repair proficient)
- You cannot have had any previous chemotherapy for the metastatic cancer (except possibly one cycle of FOLFOX or CAPOX without a scan)
- Your primary rectal tumor must still be there and not have received radiation before
- You must be in fairly good health (ECOG performance status 0 or 1) with no serious heart, lung, or bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and radiation before surgery for people with a specific type of high-risk rectal cancer. The goal is to see if adding these drugs can improve treatment results.
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and bevacizumab given before surgery for locally advanced rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Rectal Neoplasms Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.